Do analysts rate TAOX or RVPH?

Reviva Pharmaceuticals has a consensus price target of $75.00, indicating a potential upside of 15,573.98%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Reviva Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has preferable earnings & valuation, RVPH or PSTV?

Plus Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Reviva Pharmaceuticals N/A N/A -$19.86M -$1.85 N/A Plus Therapeutics N/A N/A -$22.39M -$2.30 N/A

Does the media prefer RVPH or PSTV?

In the previous week, Reviva Pharmaceuticals had 6 more articles in the media than Plus Therapeutics. MarketBeat recorded 7 mentions for Reviva Pharmaceuticals and 1 mentions for Plus Therapeutics. Reviva Pharmaceuticals' average media sentiment score of 0.82 beat Plus Therapeutics' score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Reviva Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, CLRB or RVPH?

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectar Biosciences N/A N/A -$21.79M -$3.84 N/A Reviva Pharmaceuticals N/A N/A -$19.86M -$1.85 N/A

Is CLRB or RVPH more profitable?

Cellectar Biosciences' return on equity of -185.35% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -185.35% -115.42% Reviva Pharmaceuticals N/A -391.58% -119.08%

Does the media prefer CLRB or RVPH?

In the previous week, Reviva Pharmaceuticals had 5 more articles in the media than Cellectar Biosciences. MarketBeat recorded 7 mentions for Reviva Pharmaceuticals and 2 mentions for Cellectar Biosciences. Reviva Pharmaceuticals' average media sentiment score of 0.82 beat Cellectar Biosciences' score of -0.87 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Reviva Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate TXMD or RVPH?

Reviva Pharmaceuticals has a consensus price target of $75.00, indicating a potential upside of 15,573.98%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Reviva Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Reviva Pharmaceuticals (RVPH) Competitors

$0.48 0.00 (-0.93%)

As of 03:59 PM Eastern

Compare

RVPH vs. TAOX, AYTU, PSTV, CLRB, and TXMD

Should you buy Reviva Pharmaceuticals stock or one of its competitors? Reviva Pharmaceuticals's main competitors and comparable companies include Synaptogenix (TAOX), Aytu BioPharma (AYTU), Plus Therapeutics (PSTV), Cellectar Biosciences (CLRB), and TherapeuticsMD (TXMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Reviva Pharmaceuticals compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Reviva Pharmaceuticals has a consensus price target of $75.00, indicating a potential upside of 15,573.98%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Reviva Pharmaceuticals had 7 more articles in the media than Synaptogenix. MarketBeat recorded 7 mentions for Reviva Pharmaceuticals and 0 mentions for Synaptogenix. Reviva Pharmaceuticals' average media sentiment score of 0.82 beat Synaptogenix's score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Synaptogenix	Neutral
Reviva Pharmaceuticals	Positive

Reviva Pharmaceuticals has lower revenue, but higher earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	97.49	-$28.74M	-$3.85	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$1.85	N/A

Reviva Pharmaceuticals has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Synaptogenix's return on equity of -128.51% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Synaptogenix has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Reviva Pharmaceuticals beats Synaptogenix on 11 of the 15 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Aytu BioPharma?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Reviva Pharmaceuticals had 7 more articles in the media than Aytu BioPharma. MarketBeat recorded 7 mentions for Reviva Pharmaceuticals and 0 mentions for Aytu BioPharma. Reviva Pharmaceuticals' average media sentiment score of 0.82 beat Aytu BioPharma's score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Reviva Pharmaceuticals	Positive
Aytu BioPharma	Neutral

Reviva Pharmaceuticals currently has a consensus target price of $75.00, indicating a potential upside of 15,573.98%. Aytu BioPharma has a consensus target price of $10.75, indicating a potential upside of 365.37%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Reviva Pharmaceuticals is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Reviva Pharmaceuticals has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

Reviva Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

Aytu BioPharma has higher revenue and earnings than Reviva Pharmaceuticals. Aytu BioPharma is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$1.85	N/A
Aytu BioPharma	$66.38M	0.37	-$13.56M	-$4.58	N/A

Summary

Reviva Pharmaceuticals beats Aytu BioPharma on 11 of the 15 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Plus Therapeutics?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Reviva Pharmaceuticals has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

Plus Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$1.85	N/A
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

In the previous week, Reviva Pharmaceuticals had 6 more articles in the media than Plus Therapeutics. MarketBeat recorded 7 mentions for Reviva Pharmaceuticals and 1 mentions for Plus Therapeutics. Reviva Pharmaceuticals' average media sentiment score of 0.82 beat Plus Therapeutics' score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Reviva Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Comparatively, 2.5% of Plus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Reviva Pharmaceuticals has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Reviva Pharmaceuticals currently has a consensus price target of $75.00, suggesting a potential upside of 15,573.98%. Plus Therapeutics has a consensus price target of $51.75, suggesting a potential upside of 1,585.67%. Given Reviva Pharmaceuticals' higher probable upside, equities research analysts clearly believe Reviva Pharmaceuticals is more favorable than Plus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Reviva Pharmaceuticals beats Plus Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Cellectar Biosciences presently has a consensus target price of $11.00, indicating a potential upside of 336.51%. Reviva Pharmaceuticals has a consensus target price of $75.00, indicating a potential upside of 15,573.98%. Given Reviva Pharmaceuticals' higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cellectar Biosciences has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

Cellectar Biosciences' return on equity of -185.35% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-185.35%	-115.42%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$1.85	N/A

In the previous week, Reviva Pharmaceuticals had 5 more articles in the media than Cellectar Biosciences. MarketBeat recorded 7 mentions for Reviva Pharmaceuticals and 2 mentions for Cellectar Biosciences. Reviva Pharmaceuticals' average media sentiment score of 0.82 beat Cellectar Biosciences' score of -0.87 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Reviva Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Reviva Pharmaceuticals beats Cellectar Biosciences on 8 of the 13 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Reviva Pharmaceuticals has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. TherapeuticsMD's return on equity of -1.09% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

In the previous week, Reviva Pharmaceuticals had 7 more articles in the media than TherapeuticsMD. MarketBeat recorded 7 mentions for Reviva Pharmaceuticals and 0 mentions for TherapeuticsMD. Reviva Pharmaceuticals' average media sentiment score of 0.82 beat TherapeuticsMD's score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
TherapeuticsMD	Neutral
Reviva Pharmaceuticals	Positive

Reviva Pharmaceuticals has a consensus price target of $75.00, indicating a potential upside of 15,573.98%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

TherapeuticsMD has higher revenue and earnings than Reviva Pharmaceuticals. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	7.93	-$570K	$0.02	103.50
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$1.85	N/A

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by company insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

TherapeuticsMD has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

Summary

Reviva Pharmaceuticals beats TherapeuticsMD on 8 of the 15 factors compared between the two stocks.

Get Reviva Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVPH vs. The Competition

Export

Metric	Reviva Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.27M	$12.53B	$7.36B	$12.81B
Dividend Yield	N/A	2.61%	2.53%	10.78%
P/E Ratio	-0.26	646.74	211.91	20.71
Price / Sales	N/A	753.83	631.75	95.36
Price / Cash	N/A	15.47	29.03	36.89
Price / Book	0.32	10.42	11.18	6.40
Net Income	-$19.86M	$2.79B	$3.46B	$347.95M
7 Day Performance	-4.74%	2.25%	1.98%	0.91%
1 Month Performance	1.25%	4.72%	7.32%	5.10%
1 Year Performance	-95.56%	7.07%	24.76%	16.16%

Reviva Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVPH Reviva Pharmaceuticals	2.7262 of 5 stars	$0.48 -0.9%	$75.00 +15,574.0%	-95.5%	$6.27M	N/A	N/A	5
TAOX Synaptogenix	0.4639 of 5 stars	$3.38 -1.7%	N/A	-49.5%	$25.70M	$300K	N/A	4	Positive News Gap Up
AYTU Aytu BioPharma	2.1588 of 5 stars	$2.36 -0.8%	$10.75 +355.5%	+7.7%	$25.55M	$66.38M	N/A	160	Positive News
PSTV Plus Therapeutics	1.9144 of 5 stars	$3.68 -0.5%	$51.75 +1,306.3%	-74.7%	$25.33M	N/A	N/A	20
CLRB Cellectar Biosciences	2.7578 of 5 stars	$2.56 -1.5%	$11.00 +329.7%	-46.9%	$24.58M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RVPH) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Reviva Pharmaceuticals (RVPH) Competitors

RVPH vs. TAOX, AYTU, PSTV, CLRB, and TXMD

How does Reviva Pharmaceuticals compare to Synaptogenix?

Summary

How does Reviva Pharmaceuticals compare to Aytu BioPharma?

Summary

How does Reviva Pharmaceuticals compare to Plus Therapeutics?

Summary

How does Reviva Pharmaceuticals compare to Cellectar Biosciences?

Summary

How does Reviva Pharmaceuticals compare to TherapeuticsMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH vs. The Competition

Reviva Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Reviva Pharmaceuticals (RVPH) Competitors

RVPH vs. TAOX, AYTU, PSTV, CLRB, and TXMD

How does Reviva Pharmaceuticals compare to Synaptogenix?

Do analysts rate TAOX or RVPH?

Does the media favor TAOX or RVPH?

Which has preferable valuation & earnings, TAOX or RVPH?

Is TAOX or RVPH more profitable?

Which has more risk and volatility, TAOX or RVPH?

Do insiders and institutionals believe in TAOX or RVPH?

Summary

How does Reviva Pharmaceuticals compare to Aytu BioPharma?

Do institutionals and insiders have more ownership in RVPH or AYTU?

Does the media prefer RVPH or AYTU?

Do analysts rate RVPH or AYTU?

Is RVPH or AYTU more profitable?

Which has more volatility & risk, RVPH or AYTU?

Which has preferable earnings & valuation, RVPH or AYTU?

Summary

How does Reviva Pharmaceuticals compare to Plus Therapeutics?

Which has more volatility & risk, RVPH or PSTV?

Which has preferable earnings & valuation, RVPH or PSTV?

Does the media prefer RVPH or PSTV?

Do insiders and institutionals hold more shares of RVPH or PSTV?

Is RVPH or PSTV more profitable?

Do analysts recommend RVPH or PSTV?

Summary

How does Reviva Pharmaceuticals compare to Cellectar Biosciences?

Do analysts recommend CLRB or RVPH?

Do institutionals & insiders believe in CLRB or RVPH?

Which has more volatility and risk, CLRB or RVPH?

Is CLRB or RVPH more profitable?

Which has better earnings and valuation, CLRB or RVPH?

Does the media prefer CLRB or RVPH?

Summary

How does Reviva Pharmaceuticals compare to TherapeuticsMD?

Is TXMD or RVPH more profitable?

Does the media prefer TXMD or RVPH?

Do analysts rate TXMD or RVPH?

Which has better valuation & earnings, TXMD or RVPH?

Do institutionals and insiders hold more shares of TXMD or RVPH?

Which has more risk and volatility, TXMD or RVPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH vs. The Competition

Reviva Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools